DRUG · Unmapped registry intervention
EPI-326
Find medicine records ·
Find other trials using this name
Clinical trial
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
NCT07462377
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Epidermal Growth Factorunresolved
Epidermal Growth Factor Receptorunresolved
Non Small Cellunresolved
Non Small Cell Lungunresolved
Head and Neckunresolved
Head and Neck Cancersunresolved
Head and Neck Squamous Cell Cancerunresolved
EGFRunresolved
Interventions
EPI-326DRUG
Sponsors & collaborators
EpiBiologicslead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07462377 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.